A pilot study using 12 patients with mixed stages of breast cancer evaluated the effect of a peptide-based vaccine formulated using 9 peptides derived from the antigens: MAGE A1, A3, and A10, CEA, NY-ESO-1, and HER2 in combination with an antagonist of TLR3 (Toll-like receptor 3) named poly-ICLC and one peptide derived from the tetanus toxoid. This evidence concerns the gene TLR3 and breast cancer.